Skip to main content
NCBI home page
Lipids in Health and Disease logoLink to Lipids in Health and Disease
. 2020 Feb 17;19:25. doi: 10.1186/s12944-020-1198-x

The effects of resveratrol on lipid profiles and liver enzymes in patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials

Maryam Akbari 1, Omid Reza Tamtaji 2, Kamran B Lankarani 3, Reza Tabrizi 1, Ehsan Dadgostar 4, Neda Haghighat 5, Fariba Kolahdooz 6, Amir Ghaderi 7,8, Mohammad Ali Mansournia 9, Zatollah Asemi 2,✉
PMCID: PMC7026982  PMID: 32066446

Abstract

Background

There are current trials investigating the effect of resveratrol supplementation on lipid profiles and liver enzymes among patients with metabolic syndrome (MetS) and related disorders; however, their findings are controversial. This systematic review and meta-analysis were aimed to determine the effects of resveratrol supplementation on lipid profiles and liver enzymes among patients with MetS and related disorders.

Methods

We performed a comprehensive search of the following online databases up to November 2018: Cochrane Library, PubMed, Embase, and Web of Science. The relevant articles were assessed for quality of studies using the Cochrane risk of bias tool.

Results

Out of 2459 citations, 31 articles were appropriate for including to the current meta-analysis. The pooled results indicated that resveratrol use significantly decreased total cholesterol [weighted mean difference (WMD) = − 7.65 mg/dL; 95% CI, − 12.93, − 2.37; P < 0.01; I2: 83.4%] and increased gamma-glutamyl transferase (GGT) concentrations (WMD = 1.76 U/l; 95% CI, 0.58, 2.94; P < 0.01; I2: 20.1%). We found no significant effect of resveratrol supplementation on triglycerides (WMD = − 5.84 mg/dL; 95% CI, − 12.68, 1.00; P = 0.09; I2: 66.8%), LDL- (WMD = -2.90 mg/dL; 95% CI, − 10.88, 5.09; P = 0.47; I2: 96.0%), HDL-cholesterol (WMD = 0.49 mg/dL; 95% CI, − 0.80, 1.78; P = 0.45; I2: 74.0%), alanine aminotransferase (ALT) (WMD = -0.14 U/l; 95% CI, − 3.69, 3.41; P = 0.93; I2: 79.6%), and aspartate aminotransferase (AST) (WMD = -0.34 U/l; 95% CI, − 2.94, 2.27; P = 0.80; I2: 88.0%) concentrations.

Conclusions

This meta-analysis demonstrated that resveratrol supplementation among patients with MetS and related disorders significantly reduced total cholesterol and increased GGT concentrations, but did not affect triglycerides, LDL-, HDL-cholesterol, ALT, and AST concentrations. This data suggests that resveratrol may have a potential cardio-protective effect in patients with MetS and related disorders.

Keywords: Resveratrol, Lipid profiles, Liver enzymes, Metabolic syndrome, Meta-analysis

Background

Increased concentrations of circulating lipid profiles are a strong risk factor for cardiovascular disease [1]; high concentrations of total-, LDL-cholesterol, or triglycerides, as well as, low concentrations of HDL-cholesterol are consistently correlated with incidence of cardiovascular diseases (CVDs) [2, 3]. Metabolic syndrome (MetS) is considered as an insulin resistant syndrome comprising impaired glucose tolerance, decreased insulin sensitivity, dyslipidemia, central obesity, and hypertension, all of which are well- established risk factors for CVDs [4]. In addition, MetS is correlated with non-alcoholic fatty liver disease (NAFLD), type 2 diabetes mellitus (T2DM), colorectal disease, atrial fibrillation and hypothyroidism [5, 6]. NAFLD is also associated with impaired liver enzymes, including, alanine aminotransferase (ALT) and aspartate aminotransferase (AST), dysfunctional fat cells, and adipose tissue insulin resistance, resulting in hyperglycemia and dyslipidemia [7, 8].

The beneficial effects of resveratrol, plant sterols, and stanols on lipid profiles and modifying cardiovascular risk factors have been reported [9–13]. Resveratrol is a natural polyphenolic compound found mainly in peanuts and in the skin of red grapes that is used as a dietary supplement to improve metabolic profiles [14]. The effects of resveratrol supplementation on lipid profiles and liver enzymes have already been evaluated; however, these findings are controversial. In a meta-analysis on seven randomized controlled trials (RCTs), conducted by Sahebkar et al. [15], resveratrol supplementation had no effect on lipid profile. In another meta-analysis conducted by Hausenblas et al. [16], resveratrol supplementation to patients with T2DM was more effective on the systolic blood pressure, hemoglobin A1c, and creatinine, but did not affect fasting glucose, insulin resistance, diastolic blood pressure, insulin, triglycerides, LDL-and HDL-cholesterol concentrations. However, another meta-analysis of then RCTs showed no effects of resveratrol supplementation on total-, LDL-cholesterol, triglycerides, and fasting glucose concentrations [17]. Differences in study design, study population’s characteristics, the dosage of resveratrol used, and the duration of intervention might explain the discrepancies among different studies.

We aimed to systematically review the trials investigating the effect of resveratrol supplementation on lipid profiles and liver enzymes and to summarize the impact among patients with MetS and related disorders.

Methods

PRISMA guideline (ERF) (the preferred reporting items for systematic reviews and meta-analyses) was used to design and implement this meta-analysis.

Search strategy

Two independent authors (MA and OT) performed a comprehensive search to identify the relevant RCTs through inception up to November 2018. Online databases, including Cochrane Library, PubMed, Embase, and Web of Science databases by using the following MeSH and text keywords: patients [“Mets” OR “NAFLD” OR “disorders related to MetS” OR “diabetes” OR “T1DM” OR “T2DM” OR “overweight” OR “obese” OR “chronic kidney disease” OR “hypertension” OR “high blood pressure” OR “dyslipidemia” OR “CVD”], intervention (“resveratrols” OR “resveratrol” AND “use” OR “supplementation” OR “intake”), and outcomes lipid profiles [“triglycerides” OR “total cholesterol” OR “LDL-cholesterol (LDL-C)” OR “HDL-cholesterol (HDL-C)”] and liver measurements [“alanine aminotransferase (ALT)” OR “aspartate aminotransferase (AST)” OR “gamma-glutamyl transferase (GGT)”]. Clinical trials retrieved that estimated the effect of resveratrol intake on lipid profiles and/or liver enzymes. Our search strategy was limited to human RCTs published in English language. We conducted a manual search in the reference list’s included articles and pervious relevant reviews to find other additional articles.

Selection criteria

The following inclusion criteria were used to select the related articles: RCTs were among humans (with parallel or cross-over design) with metabolic diseases, administrated resveratrol supplements in the intervention group and received placebo in the comparison group, contained sufficient data on mean changes of lipid profiles (including, triglycerides, total-, LDL-, and HDL-cholesterol concentrations), and liver enzymes (ALT, AST, and GGT concentrations), along with standard deviation (SD) or related 95% confidence intervals (CIs) at the baseline and at the end of trial for the intervention and placebo groups. RCTs which were not placebo controlled or other type of studies including animal, in vitro, case report, and case series, also abstracts or protocols without full texts, and studies with dosage of resveratrol lower than 20 mg/day were excluded.

Data extraction

Two independent investigators (MA and OT) extracted data using a standard Excel forms according to the following items: first author’s name, publication year, country, demographic characteristics of participants, study methods, sample size (intervention/placebo groups), dose of treatment, type of intervention, type of diseases, the mean ± (SD) of changes for triglycerides, total-, LDL-, HDL-cholesterol, ALT, AST, and GGT concentrations in the intervention and placebo groups at the baseline and at the end of intervention. If the outcomes were reported by different doses, types of supplements, or duration of the intervention, we treated each situation as a separate study. Disagreements were resolved by discussion with a third author (ZA).

Quality assessment

The Cochrane Collaboration risk of bias tool was applied to assess the quality of selected RCTs using the following domains: “randomization generation, allocation concealment, blinding of participants and outcome assessment, incomplete outcome data and selective outcome reporting, and the other sources of bias”.

Statistical analysis

All statistical analyses were conducted using STATA software version 12.0 (Stata Corp., College Station, TX) and RevMan V.5.3 software (Cochrane Collaboration, Oxford, UK). Weighted mean differences (WMDs) and 95% CIs were considered as the overall combined effect sizes. Heterogeneity across included trials was examined using the Cochrane’s Q and I2 statistics. I2 > 50% with P < 0.05 indicated that a significant heterogeneity exists, therefore, the DerSimonian and Laird random effects model were used to combine effect sizes; otherwise, the inverse variance fixed-effect model was applied. Sensitivity analyses were performed to evaluate the impact of each included clinical trials on the validity of the overall combined WMDs. Subgroup analyses were conducted to examine the source of heterogeneity according to the following possible moderator variables; type of interventions (resveratrol plus other nutrients or drugs vs. resveratrol alone), dosage of resveratrol (> 250 vs. ≤250 mg/day), duration of intervention (≤8 vs. > 8 weeks), and type of chronic condition (e.g. overweight, or obese, or other chronic diseases vs. T2DM). The potential evidence of publication bias was determined using Egger’s- and Begg’s-test. P-value less than 0.05 were considered as statistically significant.

Results

In initial online database searches, 2459 reports were identified. After removing duplicates citations by reviewing titles and abstracts and excluding the irrelevant citations, 31 studies (35 effect sizes) were finally included. Figure 1 shows the stepwise with more details of the identification and selection of the relevant articles. All 35 included effect sizes were randomized, placebo-controlled trial. Twenty-nine studies were conducted using parallel design and six studies had cross-over design. The total number of the participants among included studies was 1722 individuals (890 persons in the resveratrol group; and 832 in the placebo group). Thirty-two studies calculated the influences of resveratrol intake on triglycerides, twenty-eighth on total cholesterol, twenty-seven on LDL-cholesterol, twenty-nine on HDL-cholesterol, thirteen on ALT, ten on AST, and five studies on GGT concentrations. The duration of resveratrol supplements ranged from four to 48 weeks and dosage of the intervention varied from 20 to 3000 mg/day among included articles. Table 1 illustrates the characteristics of the included articles. The quality assessment of included articles performed by authors’ judgment according to each bias item is presented in Fig. 2.

Fig. 1.

Fig. 1

Open in a new tab

Literature search and review flowchart for selection of studies

Table 1.

Characteristics of included studies

Authors (Ref) Publication year Sample size (control/intervention) Population/Country Intervention (name and daily dose) Duration Presented data Age (y) (control, intervention)
Arzola-Paniagua (a) et al. [18] 2016 24/15 Obesity/Mexico Resveratrlol 300 mg 24 weeks TG 33.7 ± 11.9, 38.8 ± 9.59
Arzola-Paniagua (b) et al. [18] 2016 21/24 Obesity/Mexico Resveratrlol 300 mg 24 weeks TG 40.96 ± 10.0, 39.76 ± 8.91
Bashmakov YK et al. [19] 2014 10/14 T2DM/Egypt Resveratrol 100 mg 2 months HDL-C, LDL-C, and TC 54 ± 10.1, 59.8 ± 6.6
Bhatt JK et al. [20] 2012 29/28 T2DM/India Resveratrol 250 mg 3 months TG, HDL-C, LDL-C, and TC 56.67 ± 8.91, 57.75 ± 8.71
Goh KP et al. [21] 2014 5/5 T2DM/Singapore Resveratrol 3000 mg 12 weeks TG, HDL-C, LDL-C, and ALT 55.8 ± 7.3, 56.8 ± 5.3
Imamura H et al. [22] 2017 25/25 T2DM/Japan Resveratrol 100 mg 12 weeks TG, HDL-C, TC 57.4 ± 10.6, 58.2 ± 10.1
Zare Javid A et al. [23] 2017 22/21 T2DM/Iran Resveratrol 480 mg 4 weeks TG 49.1 ± 7.4, 50.9 ± 8.9
Kjær TN et al. [24] (a) 2017 12/21 MetS/Denmark Resveratrol 150 mg 16 weeks TG, HDL-C, LDL-C, TC, and ALT 49.1 ± 6.69, 47.8 ± 6.36
Kjær TN et al. [24] (b) 2017 12/21 MetS/Denmark Resveratrol 1000 mg 16 weeks TG, HDL-C, LDL-C, TC, and ALT 51.9 ± 5.86, 47.8 ± 6.36
Kumar BJ et al. [25] 2013 29/28 T2DM/India Resveratrol 250 mg 6 months TG, HDL-C, LDL-C, and TC 56.67 ± 8.91, 57.75 ± 8.71
Militaru C et al. [26] (a) 2013 29/29 Stable angina/Romania Resveratrol 20 mg 2 months TG, HDL-C, LDL-C, and TC 64.9 ± 5.8, 64.2 ± 7.1
Militaru C et al. [26] (b) 2013 29/29 Stable angina/Romania Resveratrol 20 mg 2 months TG, HDL-C, LDL-C, and TC 66.3 ± 5.5, 63.7 ± 6.2
Most J et al. [27] 2016 20/18 Obese/Netherlands Resveratrol 80 mg + 282 mg epigallocatechin-3-gallate 12 weeks TG, HDL-C, LDL-C, and TC 36.1 ± 9.33, 38.7 ± 9.83
Movahed A et al. [28] 2013 31/33 T2DM/Iran Resveratrol 1000 mg 45 days TG, HDL-C, LDL-C, TC, ALT,AST, and GGT 52.45 ± 6.18, 51.81 ± 6.99
Poulsen MM et al. [29] 2013 12/12 Obese/ Denmark Resveratrol 1500 mg 4 weeks TG, HDL-C, LDL-C, TC, and ALT 44.7 ± 12.12, 31.9 ± 10.03
Seyyedebrahimi S et al. [30] 2018 23/23 T2DM/ Iran Resveratrol 800 mg 2 months TG, HDL-C, LDL-C, TC, ALT, and AST 54.96 ± 6.37, 58.72 ± 6.06
Méndez-del Villar M et al. [31] 2014 10/11 MetS/ Mexico Resveratrol 1500 mg 3 months TG, HDL-C, LDL-C, and TC 39.8 ± 5.4, 40.3 ± 5.4
Witte AV et al. [32] 2014 23/23 Overweight subjects/Germany Resveratrol 200 mg 26 weeks TG and TC 64.8 ± 6.8, 63.7 ± 5.3
Chachay VS et al. [33] 2014 10/10 NAFLD/Australia Resveratrol 3000 mg 8 weeks TG, HDL-C, LDL-C, TC, ALT, and AST 48.8 ± 12.2, 47.5 ± 11.2
Chen S et al. [34] 2015 30/30 NAFLD/China Resveratrol 300 mg 12 weeks TG, HDL-C, LDL-C, TC, ALT, AST, and GGT 45.2 ± 10.0, 43.5 ± 11.0
Faghihzadeh F et al. [35] 2015 25/25 NAFLD/Iran Resveratrol 500 mg 12 weeks TG, HDL-C, LDL-C, TC, ALT, AST, and GGT 44.04 ± 10.10, 46.28 ± 9.52
Kantartzis K et al. [36] 2018 52/53 Overweight and insulin resistant Subjects/Germany Resveratrol 150 mg 12 weeks TG, HDL-C, LDL-C, TC, ALT, AST, and GGT 18–70
Most J et al. [37] 2018 14/11 Obesity/Netherlands Resveratrol 80 mg + 282 mg epigallocatechin-3-gallate 12 weeks TG 36 ± 3, 40 ± 3
Khodabandehloo H et al. [38] 2018 20/25 T2DM/Iran Resveratrol 800 mg/day 8 weeks TG, HDL-C, LDL-C, TC, ALT, and AST 56.48 ± 6.72, 61.10 ± 5.61
Chekalina NL et al. [39] 2016 33/30 CAD/Ukraine Resveratrol 100 mg 2 months TG, HDL-C, LDL-C, and TC 48–72
Fujitaka K et al. [40] 2011 17/17 MetS/Japan Trans resveratrol 100 mg (Longevinex) 3 months TG, HDL-C, and LDL-C

63 ± 9,

62 ± 14
Cicero AF et al. [41] 2016 0verall 25 Hypercholesterolemic/Italy Resveratrol 20 mg and monacolins from M. purpureus 10 mg 4 weeks TG, HDL-C, LDL-C, TC, ALT, and AST 18–70
Biesinger S et al. [42] 2016 Overall 18 Hypertension/USA Resveratrol 60 mg 4 weeks TG, HDL-C, LDL-C, and TC 44 ± 3
Timmers S et al. [43] 2011 Overall 11 Obesity/Netherlands Resveratrol 150 mg 30 days TG 52.5 ± 6.95, 52.5 ± 6.95
van der Made SM et al. [44] 2015 Overall 45 Obesity/Netherlands Resveratrol 150 mg 4 weeks HDL-C and TC 61 ± 7
de light M et al. [45] 2018 Overall 13 T2DM/Netherlands Resveratrol 150 mg 30 days HDL-C, LDL-C, TC, AST, and GGT 66 ± 7.7
Simental-Mendía LE et al. [46] 2019 31/31 Dyslipidemia/México Resveratrol 100 mg 8 weeks TG, HDL-C, LDL-C, and TC 20–65
Fodor K et al. [47](a) 2018 46/81 Stroke/Romania Resveratrol 100 mg + Allopathic treatment + physical rehabilitation 48 weeks TG, HDL-C, LDL-C, and TC 65.03 ± 8.24, 64.78 ± 6.32
Fodor K et al. [47](b) 2018 46/55 Stroke/Romania Resveratrol 200 mg + Allopathic treatment + physical rehabilitation 48 weeks TG, HDL-C, LDL-C, and TC 64.52 ± 8.05, 64.78 ± 6.32
Mazza A et al. [48] 2018 30/30 Hypertensive and hypercholesterolemic subjects/Italy Nutraceutical compounds capsule containing resveratrol 20 mg + standardized Mediterranean diet 4 weeks TG, HDL-C, LDL-C, TC, ALT, and AST 51.5 ± 7.8, 53.0 ± 8.1
Open in a new tab

CAD Coronary artery disease, MetS Metabolic syndrome, NAFLD Non-alcoholic fatty liver disease, NR Not reported, T2DM Type 2 diabetes mellitus, LDL-C Low-density lipoprotein-cholesterol, HDL-C High-density lipoprotein-cholesterol, ALT Alanine aminotransferase, AST Aspartate aminotransferase, GGT Gamma-glutamyl transferase

Fig. 2.

Fig. 2

Open in a new tab

The summary of review authors’ judgments about each risk of bias item for each included study

Main outcomes

Effects of resveratrol supplementation on lipid profiles and liver enzymes

The impact of resveratrol supplementation on lipid profiles and liver enzymes are indicated in Fig. 3. The combined findings, using random-effects model showed that resveratrol intake significantly decreased total cholesterol (= − 7.65 mg/dL; 95% CI, − 12.93, − 2.37; P < 0.01; I2: 83.4%) and increased GGT concentrations (WMD = 1.76 U/l; 95% CI, 0.58, 2.94; P < 0.01; I2: 20.1%). We found no significant effect of resveratrol intake on triglycerides (WMD = -5.84 mg/dL; 95% CI, − 12.68, 1.00; P = 0.09; I2: 66.8%), LDL- (WMD = -2.90 mg/dL; 95% CI, − 10.88, 5.09; P = 0.47; I2: 96.0%), HDL-cholesterol (WMD = 0.49 mg/dL; 95% CI, − 0.80, 1.78; P = 0.45; I2: 74.0%), ALT (WMD = -0.14 U/l; 95% CI, − 3.69, 3.41; P = 0.93; I2: 79.6%), and AST (WMD = -0.34 U/l; 95% CI, − 2.94, 2.27; P = 0.80; I2: 88.0%) concentrations.

Fig. 3.

Fig. 3

Open in a new tab

A-G Meta-analysis standardized mean differences estimates for (a) triglycerides (b) for total-, (c) for LDL-, (d) for HDL-cholesterol, (e) for ALT, (f) for AST, and (g) for GGT concentrations in the resveratrol and control groups (CI = 95%)

Subgroup analyses

The findings of subgroup analyses indicated that there were no significant changes between before and after subgroup analyses combined WMDs for lipid profiles and liver enzymes. The results of subgroup analyses are indicated in Table 2.

Table 2.

The association between resveratrol intake on lipid profiles and liver enzymes using subgroup analysis

Variables Number of WMD included Subgroups Pooled WMD (random effect) 95% CI I2 (%) Overall I2 (%)
Triglycerides 32 Overall -5.84 −12.68, 1.00 66.8 66.8
Type of intervention 6 Resveratrol plus other nutrients or drugs −8.81 −13.67, − 3.96 0.0
26 Resveratrol −5.06 − 14.41, 4.29 71.8
Dosage of resveratrol (mg/day) 10 ≥ 500 mg resveratrol 1.43 −7.84, 10.69 0.0
22 <  500 mg resveratrol −8.07 −16.20, 0.05 74.1
Duration of study (week) 14 <  12 weeks −4.93 −19.17, 9.31 70.8
18 ≥ 12 weeks −5.40 −11.53, 0.74 40.5
Type of disease 8 Overweight or obese 1.44 −13.46, 16.34 0.0
16 Other −5.41 −15.72, 4.91 74.1
8 T2DM −8.06 −21.30, 5.17 58.4
Total cholesterol 28 Overall −7.65 −12.93, − 2.37 83.4 83.4
Type of intervention 5 Resveratrol plus other nutrients or drugs −18.10 −27.80, −8.39 80.5
23 Resveratrol −4.02 −10.53, 2.49 84.4
Dosage of resveratrol (mg/day) 9 ≥ 500 mg resveratrol −2.47 −13.62, 8.67 64.3
19 <  500 mg resveratrol −10.07 −15.81, −4.33 84.2
Duration of study (week) 15 <  12 weeks −8.61 −16.64, −0.57 78.5
13 ≥ 12 weeks −5.29 −14.06, 3.49 87.6
Type of disease 5 Overweight or obese 1.93 −5.65, 9.50 0.0
15 Other −8.32 −16.28, −0.36 83.8
8 T2DM −9.68 −21.12, 1.76 83.4
LDL-cholesterol 27 Overall −2.90 −10.88, 5.09 96.0 96.0
Type of intervention 5 Resveratrol plus other nutrients or drugs −17.61 −29.20, −6.01 92.2
22 Resveratrol 0.84 −8.72, 10.39 96.1
Dosage of resveratrol (mg/day) 10 ≥ 500 mg resveratrol 5.47 −9.90, 20.84 93.8
17 <  500 mg resveratrol −9.89 −15.45, −4.33 86.2
Duration of study (week) 14 <  12 weeks −7.38 −15.47, 0.71 85.9
13 ≥ 12 weeks 0.59 −12.65, 13.84 97.6
Type of disease 3 Overweight or obese 3.47 −6.35, 13.29 0.0
16 Other −2.94 −14.71, 8.82 97.0
8 T2DM −5.10 −16.01, 5.80 88.1
HDL-cholesterol 29 Overall 0.49 −0.80, 1.78 74.0 74.0
Type of intervention 5 Resveratrol plus other nutrients or drugs 2.31 0.63, 3.98 44.4
24 Resveratrol −0.02 −1.52, 1.49 73.4
Dosage of resveratrol (mg/day) 10 ≥ 500 mg resveratrol 0.55 −2.21, 3.32 78.2
19 <  500 mg resveratrol 0.31 −1.11, 1.72 69.1
Duration of study (week) 15 <  12 weeks 0.26 −1.66, 2.18 72.1
14 ≥ 12 weeks 0.79 − 0.92, 2.50 71.1
Type of disease 4 Overweight or obese −0.46 −2.51, 1.59 0.0
16 Other 0.61 −1.55, 2.76 69.3
9 T2DM 0.63 −1.43, 2.70 74.3
ALT 13 Overall −0.14 −3.69, 3.41 79.6 79.6
Type of intervention 2 Resveratrol plus other nutrients or drugs 2.00 −1.56, 5.56 25.2
11 Resveratrol −0.74 −4.88, 3.41 78.9
Dosage of resveratrol (mg/day) 9 ≥ 500 mg resveratrol −1.77 −6.37, 2.84 80.8
4 <  500 mg resveratrol 2.19 −0.51, 4.89 0.0
Duration of study (week) 7 <  12 weeks 1.52 −0.39, 3.43 0.0
11 ≥ 12 weeks −2.01 −8.09, 4.08 78.2
Type of disease 2 Overweight or obese 1.34 −5.36, 8.04 0.0
7 Other −1.76 −7.00, 3.48 83.8
4 T2DM 1.75 −1.43, 4.92 27.3
AST 10 Overall −0.34 −2.94, 2.27 88.0 88.0
Type of intervention 2 Resveratrol plus other nutrients or drugs −2.22 −11.24, 6.79 93.7
8 Resveratrol 0.18 −2.70, 3.05 87.5
Dosage of resveratrol (mg/day) 6 ≥ 500 mg resveratrol 0.28 −3.78, 4.35 84.1
4 <  500 mg resveratrol −0.83 −4.42, 2.76 87.5
Duration of study (week) 7 <  12 weeks 0.96 −1.92, 3.84 79.1
3 ≥ 12 weeks −3.16 −6.43, 0.12 76.1
Type of disease 1 Overweight or obese −0.12 −3.54, 3.30 –
5 Other −2.61 −6.29, 1.06 83.6
4 T2DM 1.23 0.30, 2.17 0.0
GGT 5 Overall 1.76 0.58, 2.94 20.1 20.1
Type of intervention – Resveratrol plus other nutrients or drugs – – –
5 Resveratrol 1.76 0.58, 2.94 20.1
Dosage of resveratrol (mg/day) 3 ≥ 500 mg resveratrol 1.05 −1.31, 3.40 55.9
2 <  500 mg resveratrol 2.00 0.63, 3.36 0.0
Duration of study (week) 2 <  12 weeks 2.01 0.71, 3.32 0.0
3 ≥ 12 weeks 0.60 −2.17, 3.37 52.2
Type of disease 1 Overweight or obese 1.74 −8.78, 12.26 –
2 Other 0.52 −2.35, 3.39 75.8
2 T2DM 2.00 0.71, 3.32 0.0
Open in a new tab

ALT Alanine aminotransferase, AST Aspartate aminotransferase, GGT Gamma-glutamyl transferase

Sensitivity analyses

Sensitivity analyses showed no significant changes between the pre- and post-sensitivity combined WMDs for triglycerides, HDL-cholesterol, ALT, AST, and GGT concentrations. We found that there were a significant effect between before and after sensitivity pooled WMD for total cholesterol after removing Bhatt et al. [20] study (WMD -5.76; 95% CI, − 12.23, 0.70), and for LDL-cholesterol after removing Faghihzadeh et al. [35] study (WMD -6.32; 95% CI, − 11.41, − 1.22) (Table 3).

Table 3.

The association between resveratrol intake and lipid profiles and liver enzymes using sensitivity analyses

Variables Pre-sensitivity analysis Upper & lower of effect size Post-sensitivity analysis
No. of studies included Pooled WMD (random effect) 95% CI Pooled WMD (random effect) 95% CI Excluded studies
Triglycerides 32 −5.84 −12.68, 1.00 Upper −4.24 −8.78, 0.29 Simental-Mendía [46]
Lower −6.86 −13.88, 0.15 Faghihzadeh [35]
Total cholesterol 28 −7.65 −12.93, −2.37 Upper −5.76 − 12.23, 0.70 Bhatt [20]
Lower −9.00 −14.11, −3.89 Faghihzadeh [35]
LDL-cholesterol 27 − 2.90 −10.88, 5.09 Upper −1.49 −9.36, 6.37 Cicero [41]
Lower −6.32 −11.41, − 1.22 Faghihzadeh [35]
HDL-cholesterol 29 0.49 −0.80, 1.78 Upper 0.69 −0.59, 1.99 Kumar [25]
Lower 0.17 −1.04, 1.40 Movahed [28]
ALT 13 − 0.14 − 3.69, 3.41 Upper − 0.33 − 4.10, 3.42 Kantartzis [36]
Lower − 0.69 −4.35, 2.96 Khodabandehloo [38]
AST 10 −0.34 − 2.94, 2.27 Upper 0.42 − 2.19, 3.03 Mazza [48]
Lower −0.77 −3.51, 1.96 Seyyedebrahimi [30]
GGT 5 1.76 0.58, 2.94 Upper 2.11 0.89, 3.34 Chen [34]
Lower 1.07 −1.22, 3.37 de Light M [45]
Open in a new tab

ALT Alanine aminotransferase, AST Aspartate aminotransferase, GGT Gamma-glutamyl transferase

Publication bias and quality assessment

Egger and Begg’s tests indicated no significant effect of possible publication bias for meta-analyses calculating the influence of resveratrol intake on triglycerides (P Begg’s test = 0.74, P Egger’s test = 0.69), LDL-cholesterol (PBg = 0.07, PEe = 0.53), HDL-cholesterol (PBg = 0.88, PEe = 0.98), ALT (PBg = 0.39, PEe = 0.11), AST (PBg = 0.42, PEe = 0.90), and GGT concentrations (PBg = 0.14, PEe = 0.60). The authors found that there was a significant effect of the potential of publication bias for total-cholesterol (PBg = 0.17, PEe = 0.00). We applied non-parametric method (Duval and Tweedie) to calculate the findings of censored articles for total-cholesterol; however, pooled WMDs findings did not statistically significant change after using Duval and Tweedie test.

Discussion

The findings of current systematic review and meta-analysis showed that resveratrol supplementation among patients with MetS and related disorders significantly reduced total cholesterol and increased GGT concentrations, but did not affect triglycerides, LDL-, HDL-cholesterol, ALT, and AST concentrations.

MetS and related disorders are characterized by changes in fatty acid metabolism, which finally results in decreased HDL-cholesterol, and increased LDL-cholesterol as well as, triglycerides concentrations. As dyslipidemia is a well-established risk factor for MetS, diabetes, and CVDs, circulating lipid profiles are routinely addressed by pharmacotherapy. We found that resveratrol supplementation among patients with MetS and related disorders significantly reduced total cholesterol, but did not affect triglycerides, LDL-, HDL-cholesterol concentrations. Previously, the effects of resveratrol on weight loss [49] and biomarkers of inflammation and oxidative stress among patients with MetS [50], and coenzyme Q10 on lipid profiles among patients diagnosed with coronary artery disease [51] were assessed. In a study conducted by Simental-Mendia et al. [46], resveratrol supplementation at a dosage of 100 mg/day for 8 weeks to individuals with dyslipidemia significantly decreased total cholesterol and triglycerides concentrations. In addition, taking resveratrol supplements at a dosage of 300 mg/day for 3 months by patients with non-alcoholic fatty liver disease significantly decreased total- and LDL-cholesterol concentrations [34]. The supplementation of resveratrol plus D-chiro-inositol for 60 days among overweight pregnant woman with an increased fasting glucose significantly reduced total-, LDL-cholesterol, and triglycerides concentrations [52]. However, in a meta-analysis conducted by Zhang et al. [53], resveratrol supplementation significantly increased total- and LDL-cholesterol concentrations. In addition, another meta-analysis found no significant effects on lipid variables following the supplementation of resveratrol in patients with T2DM [16]. The hypocholesterolemic effect of resveratrol may be mediated by its phenolic hydroxyls contain that lead to oxidation of the unsaturated fatty acids and decreasing circulating cholesterol [54]. In addition to the beneficial effects of resveratrol on lipid metabolism, the anti-atherosclerotic activity of resveratrol involves enhanced activity of peroxisome proliferator-activated receptor α [55], suppressing platelet aggregation [56], reduced blood pressure [43], and improvement of the endothelial activity [57]. Therefore, it is expected that resveratrol administration among patients with MetS and related disorders exerts a potential cardioprotective impact.

The current meta-analysis demonstrated that taking resveratrol supplements by patients with MetS and related disorders was associated with a significant reduction in GGT, but did not affect ALT and AST concentrations. In a study by Asghari et al. [58], resveratrol supplementation at a dosage of 600 mg/day for 12 weeks to patients with NAFLD did not modify liver enzymes and oxidative/anti-oxidative status. In addition, previous animal studies have claimed that resveratrol protects the liver against steatosis [59] and decreases intracellular lipids in the liver [60]. In another study, Heebøll et al. [61] demonstrated no significant improvement in the intrahepatic lipid content and the circulating concentrations of liver enzymes following resveratrol supplementation at a dosage of 1500 mg/day for 6 months among patients with NAFLD. An 8-week resveratrol supplementation at a dosage of 3000 mg/day, not only failed to show any significant improvements in NAFLD features, but also significantly increased liver enzymes concentrations [33]. Also, Faghihzadeh et al. [62] demonstrated that 500 mg/day resveratrol supplementation for 3 months among people with NAFLD significantly improved liver steatosis and ALT concentrations. A similar study with 600 mg/day resveratrol also documented a significant improvement in liver enzymes concentrations without any changes in liver steatosis degree [34]. These inconsistent findings could be related to the stage of disease, type of diseases, the method of measuring liver fat content, different dosage of resveratrol used, or baseline metabolic characteristics of the participants.

Conclusions

This meta-analysis demonstrated that resveratrol supplementation to the patients with MetS and related disorders significantly reduced total cholesterol and increased GGT concentrations, but did not affect triglycerides, LDL-, HDL-cholesterol, ALT, and AST concentrations. Therefore, resveratrol supplementation to patients with MetS and related disorders may have a potential cardio-protective effect through the reduction of total cholesterol and GGT concentrations.

Acknowledgements

The present study was supported by a grant from the Vice-chancellor for Research, SUMS, Shiraz, and Iran.

Abbreviations

ALT

Alanine aminotransferase

AST

Aspartate aminotransferase

CADs

Coronary artery diseases

GGT

Gamma-glutamyl transferase

HDL-C

High-density lipoprotein-cholesterol

LDL-C

Low-density lipoprotein-cholesterol

MetS

Metabolic syndrome

NAFLD

Non-alcoholic fatty liver disease

NR

Not reported

T2DM

Type 2 diabetes mellitus

Authors’ contributions

ZA contributed in conception, design, statistical analysis and drafting of the manuscript. MA, O-RT, K-BL, RT, ED, NH, FK, AG and M-AM contributed in data collection and manuscript drafting. All authors approved the final version for submission. ZA oversaw the study.

Funding

The present study was founded by a grant from the Vice Chancellor for Research, Shiraz University of Medical Sciences, in Iran.

Availability of data and materials

The primary data for this study is available from the authors on direct request.

Ethics approval and consent to participate

This study was considered exempt by the SUMS Institutional Review Board.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Footnotes

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Contributor Information

Maryam Akbari, Email: m.akbari45@yahoo.com.

Omid Reza Tamtaji, Email: tamtaji.or@gmail.com.

Kamran B. Lankarani, Email: lankaran@sums.ac.ir

Reza Tabrizi, Email: kmsrc89@gmail.com.

Ehsan Dadgostar, Email: Ehsandadgostar71@gmail.com.

Neda Haghighat, Email: neda.hag@gmail.com.

Fariba Kolahdooz, Email: Kolahdooz100@yahoo.com.

Amir Ghaderi, Email: gaderiam@yahoo.com.

Mohammad Ali Mansournia, Email: mansournia_ma@yahoo.com.

Zatollah Asemi, Email: asemi_r@yahoo.com.

References

  • 1.Nelson RH. Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care. 2013;40:195–211. doi: 10.1016/j.pop.2012.11.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Lemieux I, Lamarche B, Couillard C, Pascot A, Cantin B, Bergeron J, et al. Total cholesterol/HDL cholesterol ratio vs LDL cholesterol/HDL cholesterol ratio as indices of ischemic heart disease risk in men: the Quebec cardiovascular study. Arch Intern Med. 2001;161:2685–2692. doi: 10.1001/archinte.161.22.2685. [DOI] [PubMed] [Google Scholar]
  • 3.Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec cardiovascular study. Circulation. 1997;95:69–75. doi: 10.1161/01.CIR.95.1.69. [DOI] [PubMed] [Google Scholar]
  • 4.Lee SW, Lee TY, Yang SS, Tung CF, Yeh HZ, Chang CS. Risk factors and metabolic abnormality of patients with non-alcoholic fatty liver disease: either non-obese or obese Chinese population. Hepatobiliary Pancreatic Dis Int. 2018;17:45–48. doi: 10.1016/j.hbpd.2018.01.007. [DOI] [PubMed] [Google Scholar]
  • 5.Wong VW, Wong GL, Tsang SW, Fan T, Chu WC, Woo J, et al. High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis. Gut. 2011;60:829–836. doi: 10.1136/gut.2011.237974. [DOI] [PubMed] [Google Scholar]
  • 6.Pagadala MR, Zein CO, Dasarathy S, Yerian LM, Lopez R, McCullough AJ. Prevalence of hypothyroidism in nonalcoholic fatty liver disease. Dig Dis Sci. 2012;57:528–534. doi: 10.1007/s10620-011-2006-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Puri P, Baillie RA, Wiest MM, Mirshahi F, Choudhury J, Cheung O, et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology. 2007;46:1081–1090. doi: 10.1002/hep.21763. [DOI] [PubMed] [Google Scholar]
  • 8.Dongiovanni P, Stender S, Pietrelli A, Mancina RM, Cespiati A, Petta S, et al. Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver. J Intern Med. 2018;283:356–370. doi: 10.1111/joim.12719. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Sahebkar A, Serban MC, Gluba-Brzozka A, Mikhailidis DP, Cicero AF, Rysz J, et al. Lipid-modifying effects of nutraceuticals: an evidence-based approach. Nutrition. 2016;32:1179–1192. doi: 10.1016/j.nut.2016.04.007. [DOI] [PubMed] [Google Scholar]
  • 10.Patti AM, Al-Rasadi K, Giglio RV, Nikolic D, Mannina C, Castellino G, et al. Natural approaches in metabolic syndrome management. Arch Med Sci. 2018;14:422–441. doi: 10.5114/aoms.2017.68717. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Cicero AFG, Colletti A, Bajraktari G, Descamps O, Djuric DM, Ezhov M, et al. Lipid lowering nutraceuticals in clinical practice: position paper from an international lipid expert panel. Arch Med Sci. 2017;13:965–1005. doi: 10.5114/aoms.2017.69326. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Sosnowska B, Penson P, Banach M. The role of nutraceuticals in the prevention of cardiovascular disease. Cardiovasc Diagn Ther. 2017;7:S21–s31. doi: 10.21037/cdt.2017.03.20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Banach M, Patti AM, Giglio RV, Cicero AFG, Atanasov AG, Bajraktari G, et al. The role of Nutraceuticals in statin intolerant patients. J Am Coll Cardiol. 2018;72:96–118. doi: 10.1016/j.jacc.2018.04.040. [DOI] [PubMed] [Google Scholar]
  • 14.Hunter PM, Hegele RA. Functional foods and dietary supplements for the management of dyslipidaemia. Nat Rev Endocrinol. 2017;13:278–288. doi: 10.1038/nrendo.2016.210. [DOI] [PubMed] [Google Scholar]
  • 15.Sahebkar A. Effects of resveratrol supplementation on plasma lipids: a systematic review and meta-analysis of randomized controlled trials. Nutr Rev. 2013;71:822–835. doi: 10.1111/nure.12081. [DOI] [PubMed] [Google Scholar]
  • 16.Hausenblas HA, Schoulda JA, Smoliga JM. Resveratrol treatment as an adjunct to pharmacological management in type 2 diabetes mellitus--systematic review and meta-analysis. Mol Nutr Food Res. 2015;59:147–159. doi: 10.1002/mnfr.201400173. [DOI] [PubMed] [Google Scholar]
  • 17.Sahebkar A, Serban C, Ursoniu S, Wong ND, Muntner P, Graham IM, et al. Lack of efficacy of resveratrol on C-reactive protein and selected cardiovascular risk factors--results from a systematic review and meta-analysis of randomized controlled trials. Int J Cardiol. 2015;189:47–55. doi: 10.1016/j.ijcard.2015.04.008. [DOI] [PubMed] [Google Scholar]
  • 18.Arzola-Paniagua MA, Garcia-Salgado Lopez ER, Calvo-Vargas CG, Guevara-Cruz M. Efficacy of an orlistat-resveratrol combination for weight loss in subjects with obesity: A randomized controlled trial. Obesity (Silver Spring, Md) 2016;24:1454–1463. doi: 10.1002/oby.21523. [DOI] [PubMed] [Google Scholar]
  • 19.Bashmakov YK, Assaad-Khalil SH, Abou Seif M, Udumyan R, Megallaa M, Rohoma KH, et al. Resveratrol promotes foot ulcer size reduction in type 2 diabetes patients. ISRN Endocrinol. 2014;2014:816307. doi: 10.1155/2014/816307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Bhatt JK, Thomas S, Nanjan MJ. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr Res. 2012;32:537–541. doi: 10.1016/j.nutres.2012.06.003. [DOI] [PubMed] [Google Scholar]
  • 21.Goh KP, Lee HY, Lau DP, Supaat W, Chan YH, Koh AF. Effects of resveratrol in patients with type 2 diabetes mellitus on skeletal muscle SIRT1 expression and energy expenditure. Int J Sport Nutr Exerc Metab. 2014;24:2–13. doi: 10.1123/ijsnem.2013-0045. [DOI] [PubMed] [Google Scholar]
  • 22.Imamura Haruki, Yamaguchi Takashi, Nagayama Daiji, Saiki Atsuhito, Shirai Kohji, Tatsuno Ichiro. Resveratrol Ameliorates Arterial Stiffness Assessed by Cardio-Ankle Vascular Index in Patients With Type 2 Diabetes Mellitus. International Heart Journal. 2017;58(4):577–583. doi: 10.1536/ihj.16-373. [DOI] [PubMed] [Google Scholar]
  • 23.Zare Javid A, Hormoznejad R, Yousefimanesh HA, Zakerkish M, Haghighi-Zadeh MH, Dehghan P, et al. The impact of resveratrol supplementation on blood glucose, insulin, insulin resistance, triglyceride, and periodontal markers in type 2 diabetic patients with chronic periodontitis. Phytother Res. 2017;31:108–114. doi: 10.1002/ptr.5737. [DOI] [PubMed] [Google Scholar]
  • 24.Kjaer TN, Ornstrup MJ, Poulsen MM, Stodkilde-Jorgensen H, Jessen N, Jorgensen JOL, et al. No beneficial effects of resveratrol on the metabolic syndrome: a randomized placebo-controlled clinical trial. J Clin Endocrinol Metab. 2017;102:1642–1651. doi: 10.1210/jc.2016-2160. [DOI] [PubMed] [Google Scholar]
  • 25.Kumar BJ, Joghee NM. Resveratrol supplementation in patients with type 2 diabetes mellitus: a prospective, open label, randomized controlled trial. Int Res J Pharm. 2013;4:246–249. doi: 10.7897/2230-8407.04552. [DOI] [Google Scholar]
  • 26.Militaru C, Donoiu I, Craciun A, Scorei ID, Bulearca AM, Scorei RI. Oral resveratrol and calcium fructoborate supplementation in subjects with stable angina pectoris: effects on lipid profiles, inflammation markers, and quality of life. Nutrition. 2013;29:178–183. doi: 10.1016/j.nut.2012.07.006. [DOI] [PubMed] [Google Scholar]
  • 27.Most J, Timmers S, Warnke I, Jocken JW, van Boekschoten M, de Groot P, et al. Combined epigallocatechin-3-gallate and resveratrol supplementation for 12 wk increases mitochondrial capacity and fat oxidation, but not insulin sensitivity, in obese humans: a randomized controlled trial. Am J Clin Nutr. 2016;104:215–227. doi: 10.3945/ajcn.115.122937. [DOI] [PubMed] [Google Scholar]
  • 28.Movahed A, Nabipour I, Lieben Louis X, Thandapilly SJ, Yu L, Kalantarhormozi M, et al. Antihyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients. Evid Based Complement Alternat Med. 2013;2013:851267. doi: 10.1155/2013/851267. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Poulsen MM, Vestergaard PF, Clasen BF, Radko Y, Christensen LP, Stodkilde-Jorgensen H, et al. High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes. 2013;62:1186–1195. doi: 10.2337/db12-0975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Seyyedebrahimi S, Khodabandehloo H, Nasli Esfahani E, Meshkani R. The effects of resveratrol on markers of oxidative stress in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial. Acta Diabetol. 2018;55:341–353. doi: 10.1007/s00592-017-1098-3. [DOI] [PubMed] [Google Scholar]
  • 31.Mendez-del Villar M, Gonzalez-Ortiz M, Martinez-Abundis E, Perez-Rubio KG, Lizarraga-Valdez R. Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Metab Syndr Relat Disord. 2014;12:497–501. doi: 10.1089/met.2014.0082. [DOI] [PubMed] [Google Scholar]
  • 32.Witte AV, Kerti L, Margulies DS, Floel A. Effects of resveratrol on memory performance, hippocampal functional connectivity, and glucose metabolism in healthy older adults. J Neurosci. 2014;34:7862–7870. doi: 10.1523/JNEUROSCI.0385-14.2014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Chachay VS, Macdonald GA, Martin JH, Whitehead JP, O'Moore-Sullivan TM, Lee P, et al. Resveratrol does not benefit patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014;12:2092–2103. doi: 10.1016/j.cgh.2014.02.024. [DOI] [PubMed] [Google Scholar]
  • 34.Chen S, Zhao X, Ran L, Wan J, Wang X, Qin Y, et al. Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial. Digest Liver Dis. 2015;47:226–232. doi: 10.1016/j.dld.2014.11.015. [DOI] [PubMed] [Google Scholar]
  • 35.Faghihzadeh F, Adibi P, Hekmatdoost A. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study. Br J Nutr. 2015;114:796–803. doi: 10.1017/S0007114515002433. [DOI] [PubMed] [Google Scholar]
  • 36.Kantartzis K, Fritsche L, Bombrich M, Machann J, Schick F, Staiger H, et al. Effects of resveratrol supplementation on liver fat content in overweight and insulin-resistant subjects: a randomized, double-blind, placebo-controlled clinical trial. Diabetes Obes Metab. 2018;20:1793–1797. doi: 10.1111/dom.13268. [DOI] [PubMed] [Google Scholar]
  • 37.Most J, Warnke I, Boekschoten MV, Jocken JWE, de Groot P, Friedel A, et al. The effects of polyphenol supplementation on adipose tissue morphology and gene expression in overweight and obese humans. Adipocyte. 2018;7:190–196. doi: 10.1080/21623945.2018.1469942. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Khodabandehloo H, Seyyedebrahimi S, Esfahani EN, Razi F, Meshkani R. Resveratrol supplementation decreases blood glucose without changing the circulating CD14(+)CD16(+) monocytes and inflammatory cytokines in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Nutr Res. 2018;54:40–51. doi: 10.1016/j.nutres.2018.03.015. [DOI] [PubMed] [Google Scholar]
  • 39.Chekalina NI, Kazakov YM, Mamontova TV, Vesnina LE, Kaidashev IP. Resveratrol more effectively than quercetin reduces endothelium degeneration and level of necrosis factor alpha in patients with coronary artery disease. Wiad Lek. 2016;69:475–479. [PubMed] [Google Scholar]
  • 40.Fujitaka K, Otani H, Jo F, Jo H, Nomura E, Iwasaki M, et al. Modified resveratrol Longevinex improves endothelial function in adults with metabolic syndrome receiving standard treatment. Nutr Res. 2011;31:842–847. doi: 10.1016/j.nutres.2011.09.028. [DOI] [PubMed] [Google Scholar]
  • 41.Cicero AF, Morbini M, Parini A, Urso R, Rosticci M, Grandi E, et al. Effect of red yeast rice combined with antioxidants on lipid pattern, hs-CRP level, and endothelial function in moderately hypercholesterolemic subjects. Ther Clin Risk Manag. 2016;12:281–286. doi: 10.2147/TCRM.S91817. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Biesinger S, Michaels HA, Quadros AS, Qian Y, Rabovsky AB, Badger RS, et al. A combination of isolated phytochemicals and botanical extracts lowers diastolic blood pressure in a randomized controlled trial of hypertensive subjects. Eur J Clin Nutr. 2016;70:10–16. doi: 10.1038/ejcn.2015.88. [DOI] [PubMed] [Google Scholar]
  • 43.Timmers S, Konings E, Bilet L, Houtkooper RH, van de Weijer T, Goossens GH, et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011;14:612–622. doi: 10.1016/j.cmet.2011.10.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.van der Made Sanne M., Plat Jogchum, Mensink Ronald P. Resveratrol Does Not Influence Metabolic Risk Markers Related to Cardiovascular Health in Overweight and Slightly Obese Subjects: A Randomized, Placebo-Controlled Crossover Trial. PLOS ONE. 2015;10(3):e0118393. doi: 10.1371/journal.pone.0118393. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.de Ligt M, Bruls YMH, Hansen J, Habets MF, Havekes B, Nascimento EBM, et al. Resveratrol improves ex vivo mitochondrial function but does not affect insulin sensitivity or brown adipose tissue in first degree relatives of patients with type 2 diabetes. Mol Metab. 2018;12:39–47. doi: 10.1016/j.molmet.2018.04.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Simental-Mendía Luis E., Guerrero-Romero Fernando. Effect of resveratrol supplementation on lipid profile in subjects with dyslipidemia: A randomized double-blind, placebo-controlled trial. Nutrition. 2019;58:7–10. doi: 10.1016/j.nut.2018.06.015. [DOI] [PubMed] [Google Scholar]
  • 47.Fodor K, Tit DM, Pasca B, Bustea C, Uivarosan D, Endres L, et al. Long-term resveratrol supplementation as a secondary prophylaxis for stroke. Oxid Med Cell Longev. 2018;2018:4147320. doi: 10.1155/2018/4147320. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Mazza A, Schiavon L, Rigatelli G, Torin G, Montanaro F, Lenti S. The short-term supplementation of monacolin K improves the lipid and metabolic patterns of hypertensive and hypercholesterolemic subjects at low cardiovascular risk. Food Funct. 2018;9:3845–3852. doi: 10.1039/C8FO00415C. [DOI] [PubMed] [Google Scholar]
  • 49.Tabrizi Reza, Tamtaji Omid Reza, Lankarani Kamran B., Akbari Maryam, Dadgostar Ehsan, Dabbaghmanesh Mohammad Hossein, Kolahdooz Fariba, Shamshirian Amir, Momen-Heravi Mansooreh, Asemi Zatollah. The effects of resveratrol intake on weight loss: a systematic review and meta-analysis of randomized controlled trials. Critical Reviews in Food Science and Nutrition. 2018;60(3):375–390. doi: 10.1080/10408398.2018.1529654. [DOI] [PubMed] [Google Scholar]
  • 50.Tabrizi R, Tamtaji OR, Lankarani KB, Mirhosseini N, Akbari M, Dadgostar E, et al. The effects of resveratrol supplementation on biomarkers of inflammation and oxidative stress among patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials. Food Funct. 2018;9:6116–6128. doi: 10.1039/C8FO01259H. [DOI] [PubMed] [Google Scholar]
  • 51.Jorat MV, Tabrizi R, Mirhosseini N, Lankarani KB, Akbari M, Heydari ST, et al. The effects of coenzyme Q10 supplementation on lipid profiles among patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials. Lipids Health Dis. 2018;17:230. doi: 10.1186/s12944-018-0876-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Malvasi A, Kosmas I, Mynbaev OA, Sparic R, Gustapane S, Guido M, et al. Can trans resveratrol plus d-chiro-inositol and myo-inositol improve maternal metabolic profile in overweight pregnant patients? Clin Ter. 2017;168:e240–e2e7. doi: 10.7417/T.2017.2013. [DOI] [PubMed] [Google Scholar]
  • 53.Zhang C, Yuan W, Fang J, Wang W, He P, Lei J, et al. Efficacy of resveratrol supplementation against non-alcoholic fatty liver disease: a meta-analysis of placebo-controlled clinical trials. PLoS One. 2016;11:e0161792. doi: 10.1371/journal.pone.0161792. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Xie HC, Han HP, Chen Z, He JP. A study on the effect of resveratrol on lipid metabolism in hyperlipidemic mice. Afr J Trad Complement Alternat Med AJTCAM. 2014;11:209–212. [PMC free article] [PubMed] [Google Scholar]
  • 55.Iannelli P, Zarrilli V, Varricchio E, Tramontano D, Mancini FP. The dietary antioxidant resveratrol affects redox changes of PPARalpha activity. Nutr Metab Cardiovasc Dis. 2007;17:247–256. doi: 10.1016/j.numecd.2005.12.011. [DOI] [PubMed] [Google Scholar]
  • 56.Shen MY, Hsiao G, Liu CL, Fong TH, Lin KH, Chou DS, et al. Inhibitory mechanisms of resveratrol in platelet activation: pivotal roles of p38 MAPK and NO/cyclic GMP. Br J Haematol. 2007;139:475–485. doi: 10.1111/j.1365-2141.2007.06788.x. [DOI] [PubMed] [Google Scholar]
  • 57.Zhang H, Zhang J, Ungvari Z, Zhang C. Resveratrol improves endothelial function: role of TNF {alpha} and vascular oxidative stress. Arterioscler Thromb Vasc Biol. 2009;29:1164–1171. doi: 10.1161/ATVBAHA.109.187146. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Asghari S, Rafraf M, Farzin L, Asghari-Jafarabadi M, Ghavami SM, Somi MH. Effects of pharmacologic dose of resveratrol supplementation on oxidative/Antioxidative status biomarkers in nonalcoholic fatty liver disease patients: a randomized, double-blind, Placebo-Controlled Trial. Adv Pharm Bull. 2018;8:307–317. doi: 10.15171/apb.2018.036. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Aguirre L, Portillo MP, Hijona E, Bujanda L. Effects of resveratrol and other polyphenols in hepatic steatosis. World J Gastroenterol. 2014;20:7366–7380. doi: 10.3748/wjg.v20.i23.7366. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Shiozaki M, Hayakawa N, Shibata M, Koike M, Uchiyama Y, Gotow T. Closer association of mitochondria with lipid droplets in hepatocytes and activation of Kupffer cells in resveratrol-treated senescence-accelerated mice. Histochem Cell Biol. 2011;136:475–489. doi: 10.1007/s00418-011-0847-6. [DOI] [PubMed] [Google Scholar]
  • 61.Heeboll S, Kreuzfeldt M, Hamilton-Dutoit S, Kjaer Poulsen M, Stodkilde-Jorgensen H, Moller HJ, et al. Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease. Scand J Gastroenterol. 2016;51:456–464. doi: 10.3109/00365521.2015.1107620. [DOI] [PubMed] [Google Scholar]
  • 62.Faghihzadeh F, Adibi P, Rafiei R, Hekmatdoost A. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. Nutr Res. 2014;34:837–843. doi: 10.1016/j.nutres.2014.09.005. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The primary data for this study is available from the authors on direct request.

Articles from Lipids in Health and Disease are provided here courtesy of BMC

RESOURCES